Comments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare ...
Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to ...